Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

American Journal of Hematology

Volumn 71, Issue 3, 2002, Pages 166-171

  Chan, Geoffrey ^a   DiVenuti, Gina ^a   Miller, Kenneth ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Danazol; Myelodysplastic syndrome; Thrombocytopenia; Treatment

Indexed keywords

DANAZOL;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SYMPTOMATOLOGY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; DANAZOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0036830106     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10209     Document Type: Article

References (20)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-1660.
2. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
3. Miller K. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. Leuk Res 1998;22(Suppl 1):S13-S16.
4. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000;95:1175-1179.
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
6. Cines DB, Cassileth PA, Kiss JE. Danazol therapy in myelodysplasia. Ann Intern Med 1985;103:58-60.
7. Kornberg A, Yona R, Iuklea S, Kaufman S. Danazol and myelodysplastic syndromes. Ann Intern Med 1986;104:445-446.
8. Buzaid AC, Garewal HS, Lippman SM, Durie BG, Katakkar SB, Greenberg BR. Danazol in the treatment of myelodysplastic syndromes. Eur J Haematol 1987;39:346-348.
9. Marini B, Bassan R, Barbui T. Therapeutic efficacy of danazol in myelodysplastic syndromes. Eur J Cancer Clin Oncol 1988;24:1481-1489.
10. Selleri C, Catalano L, De Rosa G, Fontana R, Notaro R, Rotoli B. Danazol: In vitro effects on human hemopoiesis and in vivo activity in hypoplastic and myelodysplastic disorders. Eur J Haematol 1991;47:197-203.
11. Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: A report on 20 cases. Br J Haematol 1994;87:205-208.
12. Hebbar M. Kaplan C, Caulier MT. Wattel E, Morel P, Wetterwald M, Bauters F, Fenaux P. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. Br J Haematol 1996;94:112-115.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
14. Stadtmauer EA, Cassileth PA, Edelstein M, Abrahm J, Schreiber AD, Nowell PC, Cines DB. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991;77:502-508.
15. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM. So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983;308:1396-1399.
16. Ahn YS, Harrington WJ, Mylvaganam R, Ayub J, Pall LM. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985;102:298-301.
17. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33:150-162.
18. Molldrem JJ, Caples M, Mavroudis D, Plante M. Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
19. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
20. Chabannon C, Molina L, Pegourie-Baudelier B, Bost M, Leger J, Hollard D. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 1994;73:3073-3080.